Cancer is a disease with complex pathological process. Current chemotherapy faces
problems such as lack of specificity, cytotoxicity, induction of multi-drug resistance and stem …

Intracellular delivery is a key step in biological research and has enabled decades of
biomedical discoveries. It is also becoming increasingly important in industrial and medical …

While prime editing enables precise sequence changes in DNA, cellular determinants of
prime editing remain poorly understood. Using pooled CRISPRi screens, we discovered that …

Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …

Small interfering RNAs (siRNAs), which downregulate gene expression guided by sequence
complementarity, can be used therapeutically to block the synthesis of disease-causing …

RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene.
To achieve the clinical potential of RNAi, delivery materials are required to transport short …

Small interfering RNA (siRNA)-based therapies are emerging as a promising new
anticancer approach, and a small number of Phase I clinical trials involving patients with …

Therapeutics that are designed to engage RNA interference (RNAi) pathways have the
potential to provide new, major ways of imparting therapy to patients,. Long, double …

In the 10 years that have passed since the Nobel prize-winning discovery of RNA
interference (RNAi), billions of dollars have been invested in the therapeutic application of …

Nanoparticles—particles in the size range 1–100 nm—are emerging as a class of
therapeutics for cancer. Early clinical results suggest that nanoparticle therapeutics can …